Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Apollo Endosurgery, Inc.APEN · Entity 114713 | Director · 10% owner | December 29, 2016 | December 30, 2016 |
| EXAGEN INC.XGN · Entity 935 | Director | June 09, 2026 | August 24, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Apollo Endosurgery, Inc.
Report date December 29, 2016 · Filed December 30, 2016
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy H.I.G. Ventures - Endosurgery, LLC | 1,451,185 |
Reported balance
After 2016-12-29 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2016-12-29 · Other · Acquired 1,451,185 · Balance 1,451,185 F1: Shares of common stock of the corporation then known as Apollo Endosurgery, Inc. ("Old Apollo") were converted into shares of the Issuer pursuant to that certain Agreement and Plan of Merger and Reorganization, dated as of September 8, 2016, by and among the Issuer, Merger Sub, Inc. and Old Apollo (the "Merger Agreement"). Pursuant to the terms of the Merger Agreement, each share of common stock was converted into 0.3163 shares of the Issuer's common stock. Following the merger, the Issuer effected a reverse stock split at a ratio of one new share for every five and one half shares of common stock outstanding. F2: These securities are held in the name of H.I.G. Ventures - Endosurgery, LLC. H.I.G. Capital, LLC has sole voting and investment control over the shares owned by H.I.G. Ventures - Endosurgery, LLC. The Managing Directors of H.I.G. Capital, LLC have shared voting and investment control over the shares owned by H.I.G. Ventures - Endosurgery, LLC. The Reporting Person is a Managing Director of H.I.G. Capital, LLC and may be deemed to be the beneficial owner of the securities held by H.I.G. Ventures - Endosurgery, LLC. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares of common stock of the corporation then known as Apollo Endosurgery, Inc. ("Old Apollo") were converted into shares of the Issuer pursuant to that certain Agreement and Plan of Merger and Reorganization, dated as of September 8, 2016, by and among the Issuer, Merger Sub, Inc. and Old Apollo (the "Merger Agreement"). Pursuant to the terms of the Merger Agreement, each share of common stock was converted into 0.3163 shares of the Issuer's common stock. Following the merger, the Issuer effected a reverse stock split at a ratio of one new share for every five and one half shares of common stock outstanding.
F2: These securities are held in the name of H.I.G. Ventures - Endosurgery, LLC. H.I.G. Capital, LLC has sole voting and investment control over the shares owned by H.I.G. Ventures - Endosurgery, LLC. The Managing Directors of H.I.G. Capital, LLC have shared voting and investment control over the shares owned by H.I.G. Ventures - Endosurgery, LLC. The Reporting Person is a Managing Director of H.I.G. Capital, LLC and may be deemed to be the beneficial owner of the securities held by H.I.G. Ventures - Endosurgery, LLC.
EXAGEN INC.
Report date June 09, 2026 · Filed August 24, 2026 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option(right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.31 · Expires 2036-06-08 | Direct | 37,500 |
Reported balance
After 2026-06-09 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2026-06-09 · Grant · Acquired 37,500 · Balance 37,500 F1: The entire number of shares subject to this option becomes fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date. F2: On August 19, 2026, the reporting person filed a Form 4 which inadvertently reported that, following his grant of 37,500 stock options, he beneficially owned 55,000 stock options. In fact, as reported in this amendment, the reporting person was granted 37,500 and beneficially owns 37,500 stock options. |
Filing footnotes · ownership attribution and instrument terms
F1: The entire number of shares subject to this option becomes fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date.
F2: On August 19, 2026, the reporting person filed a Form 4 which inadvertently reported that, following his grant of 37,500 stock options, he beneficially owned 55,000 stock options. In fact, as reported in this amendment, the reporting person was granted 37,500 and beneficially owns 37,500 stock options.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
RxSight, Inc.
Report date August 03, 2021 · Filed August 05, 2021
Section 16 reporting ended · disclosed 2021-08-05. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 1,385,037 |
Reported balance
After 2021-08-03 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2021-08-03 · Conversion · Acquired 1,385,037 · Balance 1,385,037 F1: All shares of the Series G Preferred Stock, par value $0.001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. F2: Shares and warrant held by H.I.G. BioVentures - Calhoun, LLC. Affiliates of H.I.G. Capital manage all aspects of H.I.G. BioVentures - Calhoun, LLC. Anthony Tamer and Sami Mnaymneh are the managing partners of H.I.G. Capital and as such have the right to direct all activities related thereto. Alex Zisson, Dr. Michael Wasserman, and the Reporting Person are the managing directors of H.I.G. BioVentures - Calhoun, LLC, an affiliate of H.I.G. Capital. The Reporting Person disclaims beneficial ownership of the shares owned by H.I.G. BioVentures - Calhoun, LLC except to the extent of his pecuniary interests therein. F3: All shares of the Series H Preferred Stock, par value $0.001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. |
| Series G Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnote | 0 |
Reported balance
After 2021-08-03 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-08-03 · Conversion · Disposed 968,054 · Balance 0 F1: All shares of the Series G Preferred Stock, par value $0.001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. F3: All shares of the Series H Preferred Stock, par value $0.001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. |
| Series H Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnote | 0 |
Reported balance
After 2021-08-03 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-08-03 · Conversion · Disposed 403,355 · Balance 0 F2: Shares and warrant held by H.I.G. BioVentures - Calhoun, LLC. Affiliates of H.I.G. Capital manage all aspects of H.I.G. BioVentures - Calhoun, LLC. Anthony Tamer and Sami Mnaymneh are the managing partners of H.I.G. Capital and as such have the right to direct all activities related thereto. Alex Zisson, Dr. Michael Wasserman, and the Reporting Person are the managing directors of H.I.G. BioVentures - Calhoun, LLC, an affiliate of H.I.G. Capital. The Reporting Person disclaims beneficial ownership of the shares owned by H.I.G. BioVentures - Calhoun, LLC except to the extent of his pecuniary interests therein. F3: All shares of the Series H Preferred Stock, par value $0.001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. |
| Series H Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnote | 60,503 |
Reported balance
After 2021-08-03 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2021-08-03 · Exercise / conversion · Acquired 60,503 · Balance 60,503 F2: Shares and warrant held by H.I.G. BioVentures - Calhoun, LLC. Affiliates of H.I.G. Capital manage all aspects of H.I.G. BioVentures - Calhoun, LLC. Anthony Tamer and Sami Mnaymneh are the managing partners of H.I.G. Capital and as such have the right to direct all activities related thereto. Alex Zisson, Dr. Michael Wasserman, and the Reporting Person are the managing directors of H.I.G. BioVentures - Calhoun, LLC, an affiliate of H.I.G. Capital. The Reporting Person disclaims beneficial ownership of the shares owned by H.I.G. BioVentures - Calhoun, LLC except to the extent of his pecuniary interests therein. F4: The warrant was automatically net exercised for Series H Preferred Stock immediately prior to the closing of the Issuer's initial public offering of its Common Stock. F3: All shares of the Series H Preferred Stock, par value $0.001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. |
| Series H Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnote | 13,628 |
Reported balance
After 2021-08-03 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2021-08-03 · Tax withholding · Disposed 46,875 · Balance 13,628 F2: Shares and warrant held by H.I.G. BioVentures - Calhoun, LLC. Affiliates of H.I.G. Capital manage all aspects of H.I.G. BioVentures - Calhoun, LLC. Anthony Tamer and Sami Mnaymneh are the managing partners of H.I.G. Capital and as such have the right to direct all activities related thereto. Alex Zisson, Dr. Michael Wasserman, and the Reporting Person are the managing directors of H.I.G. BioVentures - Calhoun, LLC, an affiliate of H.I.G. Capital. The Reporting Person disclaims beneficial ownership of the shares owned by H.I.G. BioVentures - Calhoun, LLC except to the extent of his pecuniary interests therein. F4: The warrant was automatically net exercised for Series H Preferred Stock immediately prior to the closing of the Issuer's initial public offering of its Common Stock. F3: All shares of the Series H Preferred Stock, par value $0.001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. |
| Series H Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnote | 0 |
Reported balance
After 2021-08-03 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2021-08-03 · Conversion · Disposed 13,628 · Balance 0 F2: Shares and warrant held by H.I.G. BioVentures - Calhoun, LLC. Affiliates of H.I.G. Capital manage all aspects of H.I.G. BioVentures - Calhoun, LLC. Anthony Tamer and Sami Mnaymneh are the managing partners of H.I.G. Capital and as such have the right to direct all activities related thereto. Alex Zisson, Dr. Michael Wasserman, and the Reporting Person are the managing directors of H.I.G. BioVentures - Calhoun, LLC, an affiliate of H.I.G. Capital. The Reporting Person disclaims beneficial ownership of the shares owned by H.I.G. BioVentures - Calhoun, LLC except to the extent of his pecuniary interests therein. F3: All shares of the Series H Preferred Stock, par value $0.001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. |
| Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.40 | IndirectSee footnote | 0 |
Reported balance
After 2021-08-03 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-08-03 · Exercise / conversion · Disposed 60,503 · Balance 0 F4: The warrant was automatically net exercised for Series H Preferred Stock immediately prior to the closing of the Issuer's initial public offering of its Common Stock. F2: Shares and warrant held by H.I.G. BioVentures - Calhoun, LLC. Affiliates of H.I.G. Capital manage all aspects of H.I.G. BioVentures - Calhoun, LLC. Anthony Tamer and Sami Mnaymneh are the managing partners of H.I.G. Capital and as such have the right to direct all activities related thereto. Alex Zisson, Dr. Michael Wasserman, and the Reporting Person are the managing directors of H.I.G. BioVentures - Calhoun, LLC, an affiliate of H.I.G. Capital. The Reporting Person disclaims beneficial ownership of the shares owned by H.I.G. BioVentures - Calhoun, LLC except to the extent of his pecuniary interests therein. F3: All shares of the Series H Preferred Stock, par value $0.001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. |
Filing footnotes · ownership attribution and instrument terms
F1: All shares of the Series G Preferred Stock, par value $0.001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock.
F2: Shares and warrant held by H.I.G. BioVentures - Calhoun, LLC. Affiliates of H.I.G. Capital manage all aspects of H.I.G. BioVentures - Calhoun, LLC. Anthony Tamer and Sami Mnaymneh are the managing partners of H.I.G. Capital and as such have the right to direct all activities related thereto. Alex Zisson, Dr. Michael Wasserman, and the Reporting Person are the managing directors of H.I.G. BioVentures - Calhoun, LLC, an affiliate of H.I.G. Capital. The Reporting Person disclaims beneficial ownership of the shares owned by H.I.G. BioVentures - Calhoun, LLC except to the extent of his pecuniary interests therein.
F3: All shares of the Series H Preferred Stock, par value $0.001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock.
F4: The warrant was automatically net exercised for Series H Preferred Stock immediately prior to the closing of the Issuer's initial public offering of its Common Stock.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 09, 2026 Filed Aug 19, 2026 22:57 UTC | EXAGEN INC. XGN · Entity 935 | GrantStock Option(right to buy) · Derivative | 37,500 | $0.00 Strike: $4.31 | $0.00 |
DisclosureSEC source: 0001274737-26-000056 · wk-form4_1787180268.xml · derivative · entry 1 Robertson Bruce C · CIK 0001289625 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,500 Underlying: Common Stock · 37,500 shares Expires 2036-06-08 F1 · derivative.exercise_date: The entire number of shares subject to this option becomes fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date. Read SEC document |
| June 09, 2026 Filed Aug 24, 2026 22:53 UTC Amendment | EXAGEN INC. XGN · Entity 935 | GrantStock Option(right to buy) · Derivative | 37,500 | $0.00 Strike: $4.31 | $0.00 |
DisclosureSEC source: 0001289625-26-000005 · wk-form4a_1787612018.xml · derivative · entry 1 Robertson Bruce C · CIK 0001289625 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,500 Underlying: Common Stock · 37,500 shares Expires 2036-06-08 F1 · derivative.exercise_date: The entire number of shares subject to this option becomes fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date. F2 · balance_after: On August 19, 2026, the reporting person filed a Form 4 which inadvertently reported that, following his grant of 37,500 stock options, he beneficially owned 55,000 stock options. In fact, as reported in this amendment, the reporting person was granted 37,500 and beneficially owns 37,500 stock options. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 23:48 UTC | RxSight, Inc. RXST · Entity 1226 | ConversionSeries H Preferred Stock · Derivative | 13,628 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-031829 · doc4.xml · derivative · entry 7 Robertson Bruce C · CIK 0001289625 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 13,628 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Shares and warrant held by H.I.G. BioVentures - Calhoun, LLC. Affiliates of H.I.G. Capital manage all aspects of H.I.G. BioVentures - Calhoun, LLC. Anthony Tamer and Sami Mnaymneh are the managing partners of H.I.G. Capital and as such have the right to direct all activities related thereto. Alex Zisson, Dr. Michael Wasserman, and the Reporting Person are the managing directors of H.I.G. BioVentures - Calhoun, LLC, an affiliate of H.I.G. Capital. The Reporting Person disclaims beneficial ownership of the shares owned by H.I.G. BioVentures - Calhoun, LLC except to the extent of his pecuniary interests therein. F2 · price: Shares and warrant held by H.I.G. BioVentures - Calhoun, LLC. Affiliates of H.I.G. Capital manage all aspects of H.I.G. BioVentures - Calhoun, LLC. Anthony Tamer and Sami Mnaymneh are the managing partners of H.I.G. Capital and as such have the right to direct all activities related thereto. Alex Zisson, Dr. Michael Wasserman, and the Reporting Person are the managing directors of H.I.G. BioVentures - Calhoun, LLC, an affiliate of H.I.G. Capital. The Reporting Person disclaims beneficial ownership of the shares owned by H.I.G. BioVentures - Calhoun, LLC except to the extent of his pecuniary interests therein. F2 · derivative.exercise_date: Shares and warrant held by H.I.G. BioVentures - Calhoun, LLC. Affiliates of H.I.G. Capital manage all aspects of H.I.G. BioVentures - Calhoun, LLC. Anthony Tamer and Sami Mnaymneh are the managing partners of H.I.G. Capital and as such have the right to direct all activities related thereto. Alex Zisson, Dr. Michael Wasserman, and the Reporting Person are the managing directors of H.I.G. BioVentures - Calhoun, LLC, an affiliate of H.I.G. Capital. The Reporting Person disclaims beneficial ownership of the shares owned by H.I.G. BioVentures - Calhoun, LLC except to the extent of his pecuniary interests therein. F2 · derivative.expiration_date: Shares and warrant held by H.I.G. BioVentures - Calhoun, LLC. Affiliates of H.I.G. Capital manage all aspects of H.I.G. BioVentures - Calhoun, LLC. Anthony Tamer and Sami Mnaymneh are the managing partners of H.I.G. Capital and as such have the right to direct all activities related thereto. Alex Zisson, Dr. Michael Wasserman, and the Reporting Person are the managing directors of H.I.G. BioVentures - Calhoun, LLC, an affiliate of H.I.G. Capital. The Reporting Person disclaims beneficial ownership of the shares owned by H.I.G. BioVentures - Calhoun, LLC except to the extent of his pecuniary interests therein. F3 · ownership.nature: All shares of the Series H Preferred Stock, par value $0.001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 23:48 UTC | RxSight, Inc. RXST · Entity 1226 | Tax withholdingSeries H Preferred Stock · Derivative | 46,875 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-031829 · doc4.xml · derivative · entry 6 Robertson Bruce C · CIK 0001289625 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 13,628 Underlying: Common Stock · 46,875 shares Expires not disclosed F2 · derivative.exercise_price: Shares and warrant held by H.I.G. BioVentures - Calhoun, LLC. Affiliates of H.I.G. Capital manage all aspects of H.I.G. BioVentures - Calhoun, LLC. Anthony Tamer and Sami Mnaymneh are the managing partners of H.I.G. Capital and as such have the right to direct all activities related thereto. Alex Zisson, Dr. Michael Wasserman, and the Reporting Person are the managing directors of H.I.G. BioVentures - Calhoun, LLC, an affiliate of H.I.G. Capital. The Reporting Person disclaims beneficial ownership of the shares owned by H.I.G. BioVentures - Calhoun, LLC except to the extent of his pecuniary interests therein. F4 · kind: The warrant was automatically net exercised for Series H Preferred Stock immediately prior to the closing of the Issuer's initial public offering of its Common Stock. F2 · price: Shares and warrant held by H.I.G. BioVentures - Calhoun, LLC. Affiliates of H.I.G. Capital manage all aspects of H.I.G. BioVentures - Calhoun, LLC. Anthony Tamer and Sami Mnaymneh are the managing partners of H.I.G. Capital and as such have the right to direct all activities related thereto. Alex Zisson, Dr. Michael Wasserman, and the Reporting Person are the managing directors of H.I.G. BioVentures - Calhoun, LLC, an affiliate of H.I.G. Capital. The Reporting Person disclaims beneficial ownership of the shares owned by H.I.G. BioVentures - Calhoun, LLC except to the extent of his pecuniary interests therein. F2 · derivative.exercise_date: Shares and warrant held by H.I.G. BioVentures - Calhoun, LLC. Affiliates of H.I.G. Capital manage all aspects of H.I.G. BioVentures - Calhoun, LLC. Anthony Tamer and Sami Mnaymneh are the managing partners of H.I.G. Capital and as such have the right to direct all activities related thereto. Alex Zisson, Dr. Michael Wasserman, and the Reporting Person are the managing directors of H.I.G. BioVentures - Calhoun, LLC, an affiliate of H.I.G. Capital. The Reporting Person disclaims beneficial ownership of the shares owned by H.I.G. BioVentures - Calhoun, LLC except to the extent of his pecuniary interests therein. F2 · derivative.expiration_date: Shares and warrant held by H.I.G. BioVentures - Calhoun, LLC. Affiliates of H.I.G. Capital manage all aspects of H.I.G. BioVentures - Calhoun, LLC. Anthony Tamer and Sami Mnaymneh are the managing partners of H.I.G. Capital and as such have the right to direct all activities related thereto. Alex Zisson, Dr. Michael Wasserman, and the Reporting Person are the managing directors of H.I.G. BioVentures - Calhoun, LLC, an affiliate of H.I.G. Capital. The Reporting Person disclaims beneficial ownership of the shares owned by H.I.G. BioVentures - Calhoun, LLC except to the extent of his pecuniary interests therein. F3 · ownership.nature: All shares of the Series H Preferred Stock, par value $0.001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 23:48 UTC | RxSight, Inc. RXST · Entity 1226 | Exercise / conversionSeries H Preferred Stock · Derivative | 60,503 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-031829 · doc4.xml · derivative · entry 5 Robertson Bruce C · CIK 0001289625 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 60,503 Underlying: Common Stock · 60,503 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Shares and warrant held by H.I.G. BioVentures - Calhoun, LLC. Affiliates of H.I.G. Capital manage all aspects of H.I.G. BioVentures - Calhoun, LLC. Anthony Tamer and Sami Mnaymneh are the managing partners of H.I.G. Capital and as such have the right to direct all activities related thereto. Alex Zisson, Dr. Michael Wasserman, and the Reporting Person are the managing directors of H.I.G. BioVentures - Calhoun, LLC, an affiliate of H.I.G. Capital. The Reporting Person disclaims beneficial ownership of the shares owned by H.I.G. BioVentures - Calhoun, LLC except to the extent of his pecuniary interests therein. F4 · kind: The warrant was automatically net exercised for Series H Preferred Stock immediately prior to the closing of the Issuer's initial public offering of its Common Stock. F2 · price: Shares and warrant held by H.I.G. BioVentures - Calhoun, LLC. Affiliates of H.I.G. Capital manage all aspects of H.I.G. BioVentures - Calhoun, LLC. Anthony Tamer and Sami Mnaymneh are the managing partners of H.I.G. Capital and as such have the right to direct all activities related thereto. Alex Zisson, Dr. Michael Wasserman, and the Reporting Person are the managing directors of H.I.G. BioVentures - Calhoun, LLC, an affiliate of H.I.G. Capital. The Reporting Person disclaims beneficial ownership of the shares owned by H.I.G. BioVentures - Calhoun, LLC except to the extent of his pecuniary interests therein. F2 · derivative.exercise_date: Shares and warrant held by H.I.G. BioVentures - Calhoun, LLC. Affiliates of H.I.G. Capital manage all aspects of H.I.G. BioVentures - Calhoun, LLC. Anthony Tamer and Sami Mnaymneh are the managing partners of H.I.G. Capital and as such have the right to direct all activities related thereto. Alex Zisson, Dr. Michael Wasserman, and the Reporting Person are the managing directors of H.I.G. BioVentures - Calhoun, LLC, an affiliate of H.I.G. Capital. The Reporting Person disclaims beneficial ownership of the shares owned by H.I.G. BioVentures - Calhoun, LLC except to the extent of his pecuniary interests therein. F2 · derivative.expiration_date: Shares and warrant held by H.I.G. BioVentures - Calhoun, LLC. Affiliates of H.I.G. Capital manage all aspects of H.I.G. BioVentures - Calhoun, LLC. Anthony Tamer and Sami Mnaymneh are the managing partners of H.I.G. Capital and as such have the right to direct all activities related thereto. Alex Zisson, Dr. Michael Wasserman, and the Reporting Person are the managing directors of H.I.G. BioVentures - Calhoun, LLC, an affiliate of H.I.G. Capital. The Reporting Person disclaims beneficial ownership of the shares owned by H.I.G. BioVentures - Calhoun, LLC except to the extent of his pecuniary interests therein. F3 · ownership.nature: All shares of the Series H Preferred Stock, par value $0.001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 23:48 UTC | RxSight, Inc. RXST · Entity 1226 | Exercise / conversionWarrant (right to buy) · Derivative | 60,503 | $0.00 Strike: $12.40 | $0.00 |
DisclosureSEC source: 0000899243-21-031829 · doc4.xml · derivative · entry 4 Robertson Bruce C · CIK 0001289625 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Series H Preferred Stock · 60,503 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · kind: The warrant was automatically net exercised for Series H Preferred Stock immediately prior to the closing of the Issuer's initial public offering of its Common Stock. F2 · price: Shares and warrant held by H.I.G. BioVentures - Calhoun, LLC. Affiliates of H.I.G. Capital manage all aspects of H.I.G. BioVentures - Calhoun, LLC. Anthony Tamer and Sami Mnaymneh are the managing partners of H.I.G. Capital and as such have the right to direct all activities related thereto. Alex Zisson, Dr. Michael Wasserman, and the Reporting Person are the managing directors of H.I.G. BioVentures - Calhoun, LLC, an affiliate of H.I.G. Capital. The Reporting Person disclaims beneficial ownership of the shares owned by H.I.G. BioVentures - Calhoun, LLC except to the extent of his pecuniary interests therein. F4 · derivative.expiration_date: The warrant was automatically net exercised for Series H Preferred Stock immediately prior to the closing of the Issuer's initial public offering of its Common Stock. F3 · ownership.nature: All shares of the Series H Preferred Stock, par value $0.001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 23:48 UTC | RxSight, Inc. RXST · Entity 1226 | ConversionSeries H Preferred Stock · Derivative | 403,355 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-031829 · doc4.xml · derivative · entry 3 Robertson Bruce C · CIK 0001289625 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 403,355 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Shares and warrant held by H.I.G. BioVentures - Calhoun, LLC. Affiliates of H.I.G. Capital manage all aspects of H.I.G. BioVentures - Calhoun, LLC. Anthony Tamer and Sami Mnaymneh are the managing partners of H.I.G. Capital and as such have the right to direct all activities related thereto. Alex Zisson, Dr. Michael Wasserman, and the Reporting Person are the managing directors of H.I.G. BioVentures - Calhoun, LLC, an affiliate of H.I.G. Capital. The Reporting Person disclaims beneficial ownership of the shares owned by H.I.G. BioVentures - Calhoun, LLC except to the extent of his pecuniary interests therein. F2 · price: Shares and warrant held by H.I.G. BioVentures - Calhoun, LLC. Affiliates of H.I.G. Capital manage all aspects of H.I.G. BioVentures - Calhoun, LLC. Anthony Tamer and Sami Mnaymneh are the managing partners of H.I.G. Capital and as such have the right to direct all activities related thereto. Alex Zisson, Dr. Michael Wasserman, and the Reporting Person are the managing directors of H.I.G. BioVentures - Calhoun, LLC, an affiliate of H.I.G. Capital. The Reporting Person disclaims beneficial ownership of the shares owned by H.I.G. BioVentures - Calhoun, LLC except to the extent of his pecuniary interests therein. F2 · derivative.exercise_date: Shares and warrant held by H.I.G. BioVentures - Calhoun, LLC. Affiliates of H.I.G. Capital manage all aspects of H.I.G. BioVentures - Calhoun, LLC. Anthony Tamer and Sami Mnaymneh are the managing partners of H.I.G. Capital and as such have the right to direct all activities related thereto. Alex Zisson, Dr. Michael Wasserman, and the Reporting Person are the managing directors of H.I.G. BioVentures - Calhoun, LLC, an affiliate of H.I.G. Capital. The Reporting Person disclaims beneficial ownership of the shares owned by H.I.G. BioVentures - Calhoun, LLC except to the extent of his pecuniary interests therein. F2 · derivative.expiration_date: Shares and warrant held by H.I.G. BioVentures - Calhoun, LLC. Affiliates of H.I.G. Capital manage all aspects of H.I.G. BioVentures - Calhoun, LLC. Anthony Tamer and Sami Mnaymneh are the managing partners of H.I.G. Capital and as such have the right to direct all activities related thereto. Alex Zisson, Dr. Michael Wasserman, and the Reporting Person are the managing directors of H.I.G. BioVentures - Calhoun, LLC, an affiliate of H.I.G. Capital. The Reporting Person disclaims beneficial ownership of the shares owned by H.I.G. BioVentures - Calhoun, LLC except to the extent of his pecuniary interests therein. F3 · ownership.nature: All shares of the Series H Preferred Stock, par value $0.001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 23:48 UTC | RxSight, Inc. RXST · Entity 1226 | ConversionSeries G Preferred Stock · Derivative | 968,054 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-031829 · doc4.xml · derivative · entry 2 Robertson Bruce C · CIK 0001289625 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 968,054 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: All shares of the Series G Preferred Stock, par value $0.001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. F1 · price: All shares of the Series G Preferred Stock, par value $0.001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. F1 · derivative.exercise_date: All shares of the Series G Preferred Stock, par value $0.001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. F1 · derivative.expiration_date: All shares of the Series G Preferred Stock, par value $0.001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. F3 · ownership.nature: All shares of the Series H Preferred Stock, par value $0.001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 23:48 UTC | RxSight, Inc. RXST · Entity 1226 | ConversionCommon Stock | 1,385,037 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-031829 · doc4.xml · nonDerivative · entry 1 Robertson Bruce C · CIK 0001289625 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,385,037 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: All shares of the Series G Preferred Stock, par value $0.001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. F2 · price: Shares and warrant held by H.I.G. BioVentures - Calhoun, LLC. Affiliates of H.I.G. Capital manage all aspects of H.I.G. BioVentures - Calhoun, LLC. Anthony Tamer and Sami Mnaymneh are the managing partners of H.I.G. Capital and as such have the right to direct all activities related thereto. Alex Zisson, Dr. Michael Wasserman, and the Reporting Person are the managing directors of H.I.G. BioVentures - Calhoun, LLC, an affiliate of H.I.G. Capital. The Reporting Person disclaims beneficial ownership of the shares owned by H.I.G. BioVentures - Calhoun, LLC except to the extent of his pecuniary interests therein. F3 · ownership.nature: All shares of the Series H Preferred Stock, par value $0.001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. Read SEC document |
| June 17, 2021 Filed Jun 21, 2021 12:39 UTC | EXAGEN INC. XGN · Entity 935 | GrantStock Option(right to buy) · Derivative | 9,000 | $0.00 Strike: $16.41 | $0.00 |
DisclosureSEC source: 0001274737-21-000076 · wf-form4_162427913125759.xml · derivative · entry 1 Robertson Bruce C · CIK 0001289625 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2031-06-16 F1 · derivative.exercise_date: The entire number of shares subject to this option becomes fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date. Read SEC document |
| June 18, 2020 Filed Jul 17, 2020 01:04 UTC | EXAGEN INC. XGN · Entity 935 | GrantStock Option(right to buy) · Derivative | 9,000 | $0.00 Strike: $13.00 | $0.00 |
DisclosureSEC source: 0001274737-20-000070 · wf-form4_159494785422469.xml · derivative · entry 1 Robertson Bruce C · CIK 0001289625 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2030-06-17 F1 · derivative.exercise_date: The entire number of shares subject to this option becomes fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date. Read SEC document |
| December 29, 2016 Filed Dec 30, 2016 13:32 UTC | Apollo Endosurgery, Inc. APEN · Entity 114713 | OtherCommon Stock | 1,451,185 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-16-033600 · edgar.xml · nonDerivative · entry 1 Robertson Bruce C · CIK 0001289625 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By H.I.G. Ventures - Endosurgery, LLC Disclosed balance after: 1,451,185 F1 · kind: Shares of common stock of the corporation then known as Apollo Endosurgery, Inc. ("Old Apollo") were converted into shares of the Issuer pursuant to that certain Agreement and Plan of Merger and Reorganization, dated as of September 8, 2016, by and among the Issuer, Merger Sub, Inc. and Old Apollo (the "Merger Agreement"). Pursuant to the terms of the Merger Agreement, each share of common stock was converted into 0.3163 shares of the Issuer's common stock. Following the merger, the Issuer effected a reverse stock split at a ratio of one new share for every five and one half shares of common stock outstanding. F1 · price: Shares of common stock of the corporation then known as Apollo Endosurgery, Inc. ("Old Apollo") were converted into shares of the Issuer pursuant to that certain Agreement and Plan of Merger and Reorganization, dated as of September 8, 2016, by and among the Issuer, Merger Sub, Inc. and Old Apollo (the "Merger Agreement"). Pursuant to the terms of the Merger Agreement, each share of common stock was converted into 0.3163 shares of the Issuer's common stock. Following the merger, the Issuer effected a reverse stock split at a ratio of one new share for every five and one half shares of common stock outstanding. F2 · ownership.nature: These securities are held in the name of H.I.G. Ventures - Endosurgery, LLC. H.I.G. Capital, LLC has sole voting and investment control over the shares owned by H.I.G. Ventures - Endosurgery, LLC. The Managing Directors of H.I.G. Capital, LLC have shared voting and investment control over the shares owned by H.I.G. Ventures - Endosurgery, LLC. The Reporting Person is a Managing Director of H.I.G. Capital, LLC and may be deemed to be the beneficial owner of the securities held by H.I.G. Ventures - Endosurgery, LLC. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.